EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death - report from ACC2024

Professor Javed Butler shared his insights on the EMPACT-MI study. The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure or death from any cause among patients with an increased risk for HF following acute myocardial infarction, according to the results of the EMPACT-MI study. Video: https://medicaldigest.org/scientific-contents/interview:empact-mi-empagliflozin-post-mi-does-not-lower-risk-first-hf-hospitalization-death